Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
Day's Change
0.0389 (37.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Nio stock drops after EV maker cut delivery guidance

7:32 am ET December 28, 2022 (MarketWatch)

By Tomi Kilgore

Nio's delivery outlook cut weighs on stocks of other China-based EV makers and Tesla

Shares of Nio Inc. took a dive Tuesday, after the China-based electric vehicle maker said it was "prudently" cutting its fourth-quarter deliveries estimate, citing COVID-related production challenges and continued supply chain constraints.

The company (NIO) said early Tuesday that it now expects to deliver 38,500 to 39,500 vehicles during the fourth quarter, down from a previous guidance range of 43,000 to 48,000 vehicles.

"In December 2022, the company has been facing challenges in deliveries and productions, together with certain supply chain constraints, caused by the outbreak of the omicron coronavirus variant in major cities in China," Nio said in a statement. "While our teams have strived to maintain continuous operations on all fronts, we were not able to reach our full capacities, particularly when there have been disruptions on delivery and registration procedures involving users."

The surge in cases comes after China starting moving on from its 2 1/2-year-long zero-COVID policy, in an effort to stem an economic downturn.

Nio's stock slumped slid 8.3% to $10.06 on Tuesday, the lowest close since Nov. 22.

Among rival China-based EV makers, shares of XPeng Inc. (XPEV) dropped 2.6% to $9.80 and Li Auto Inc. (LI) shed 1.2% to $18.54.

Shares of Tesla Inc. (TSLA), which generated about 24% of its total third-quarter revenue from China, took an 11.4% hit to suffer a seventh-straight loss. The Texas-based EV maker said over the weekend that it extended the production suspension at its plant in Shanghai, as COVID infections surged.

Don't miss: Tesla stock is the most oversold it has ever been.

Nio's stock has lost 41.5% over the past three months, while shares of XPeng have slid 28.5%, Li Auto have declined 27.9% and Tesla have tumbled 61.4%. In comparison, the iShares China Large-Cap exchange-traded fund (FXI) has gained 9.8% and the S&P 500 index has tacked on 5.0% the past three months.

-Tomi Kilgore


(END) Dow Jones Newswires

December 28, 2022 07:32 ET (12:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.